

August 23, 2024

To,

BSE Limited

Phiroze Jeejeebhoy Towers,

Dalal Street,

Mumbai- 400 001.

BSE Script Code: 531599

National Stock Exchange of India Ltd.

Exchange Plaza, Plot no. C/1, G Block,

Bandra-Kurla Complex, Bandra (E),

Mumbai - 400 051.

NSE Symbol: FDC

Sub:- US - FDA Inspection at Company's manufacturing facility located at Baddi, Himachal Pradesh

Ref.: Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and disclosure Requirements) Regulations, 2015.

Dear Sir/ Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to inform you that U.S. Food and Drug Administration (FDA) had conducted an inspection at Company's manufacturing facility located at Baddi, Himachal Pradesh which is dedicated for manufacturing Cephalosporin Oral dosage forms.

The said audit has been successfully completed by the US FDA with "No observations" (Zero 483's).

Kindly take the above on record.

Yours truly,

For FDC LIMITED

VARSHARA
NI
RAJARAM
KATRE

Digitally signed
by VARSHARANI
RAJARAM KATRE
Date: 2024.08.23
14:45:54 +05'30'

Varsharani Katre

Company Secretary & Compliance Officer

Membership No.: FCS-8948